Home › Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain
 

Keywords :   


Trevena Announces Positive Results From Phase 2b Study Of TRV130 In Acute Postoperative Pain

2015-09-02 07:04:14| drugdiscoveryonline News Articles

Trevena, Inc., a clinical stage pharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors (GPCRs), recently announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate to severe acute postoperative pain after abdominoplasty surgery

Tags: results study positive phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
04.10Should you tip even if the service wasn't worth it?
04.10Hurricane Kirk Graphics
04.10Hurricane Kirk Forecast Discussion Number 22
04.10Tropical Storm Leslie Forecast Discussion Number 10
04.10Hurricane Kirk Wind Speed Probabilities Number 22
04.10Hurricane Kirk Public Advisory Number 22
04.10Summary for Hurricane Kirk (AT2/AL122024)
04.10Tropical Storm Leslie Public Advisory Number 10
More »